Search Results

Business

Cydan announced that Imran A. Babar, PhD, has been named to the leadership team as chief business officer to help the company advance new and innovative therapies for patients living with rare monogenetic diseases.

April 9, 2018

·

2 min read

Business

Cambridge’s Cydan Scores $34M, Names a New CMO

Cydan snagged $34M to fund its rare disease pipeline and also tapped two new members of its executive leadership team.

October 17, 2017

·

2 min read

·

Alex Keown

Business

Cydan Expands Team to Accelerate Development of Innovative Treatments for Patients Living with Rare Diseases

Yongchang Qiu, Ph.D., Named Vice President, Preclinical Development; Ryan Tyler, Ph.D., Named Senior Director, Preclinical Research; Niels Svenstrup, Ph.D., Promoted to Senior Vice President, Development

March 20, 2019

·

6 min read

Cydan

Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.

Business

Cydan Announces Formation of Tiburio Therapeutics Inc. to Develop Treatments for Rare Neuroendocrine Tumors and Endocrine Diseases

Tiburio raises $31M in a Series A round to advance two clinical stage compounds TBR-760, for the treatment of nonfunctioning pituitary adenoma (NFPA), and TBR-065 for rare endocrine diseases

January 3, 2019

·

7 min read

Press Releases

Radiant Biotherapeutics Appoints Deborah Geraghty, Ph.D., as President and Chief Executive Officer

July 10, 2025

·

5 min read

Business

Cydan Announces The Promotion Of James Mcarthur, Ph.D. To President, Research And Development

October 11, 2016

·